We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca’s Calquence Fails to Help Hospitalized COVID-19 Patients
AstraZeneca’s Calquence Fails to Help Hospitalized COVID-19 Patients
AstraZeneca has announced that its blood cancer drug, Calquence (acalabrutinib), failed to reduce COVID-19-linked respiratory failure or death in two clinical trials.